**TITLE: Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease**

Theresa J Hydes1,2, Daniel J Cuthbertson1,2, Daniel H Palmer3, Omar Elshaarawy2, Philip J Johnson3, Rashika Fernando2, Timothy J Cross2, 3

**1** Department of Cardiovascular and MetabolicMedicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L9 7AL

2 Liverpool University Hospital NHS Foundation Trust, Liverpool

3 Molecular & Clinical Cancer Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L69 7BE

**Corresponding author**

Dr Theresa Hydes MBBS BSc PhD

NIHR Clinical Lecturer in Hepatology

Department of Cardiovascular and Metabolic Medicine

Institute of Life Course and Medical Sciences

Clinical Sciences Building (3rd floor)

University Hospital Aintree NHS Foundation Trust, L9 7AL

Email: theresa.hydes@liverpool.ac.uk

Tel: 0151 529 0228

**Abstract**

International guidelines recommend six monthly ultrasound as the primary surveillance tool for patients at risk of hepatocellular carcinoma (HCC). The dominant driver of liver disease in HCC surveillance populations is shifting, particularly in Europe and the United States, from chronic viral hepatitis (B or C), towards non-alcoholic fatty liver disease (NAFLD). Today, the population of individuals requiring HCC surveillance is also characterised by a high prevalence of overweight/obesity. These patient characteristics significantly impair ultrasound quality which can impede the detection of early HCC lesions. This diagnostic limitation has significant implications considering that eligibility for curative treatment depends upon the stage at which the cancer is detected. In this narrative review, we provide a comprehensive overview of the published evidence and of national/international guidelines regarding ultrasound surveillance for HCC in people with NAFLD. We examine ultrasound sensitivity in this cohort for the detection of all stage and early HCC, the impact of steatosis and abdominal obesity on ultrasound performance, evidence for the addition of serum alpha-fetoprotein measurement, optimal timing of surveillance, emerging modalities for risk stratification and screening, and outline the challenges of case finding and surveillance eligibility criteria in this patient cohort. Finally, amalgamating all available evidence, we propose a pragmatic surveillance pathway for patients with NAFLD.

**Keywords:** Non-alcoholic Fatty Liver Disease, hepatocellular carcinoma, ultrasound scan, steatosis, obesity.

**Introduction**

# Primary liver cancer (PLC) is the 11th leading cause of cancer globally and 8th leading cause of cancer death, accounting for 12.5 million disability-adjusted life years.1 Hepatocellular carcinoma (HCC) accounts for approximately 90% of PLC cases.2 HCC is strongly associated with age, male gender, diabetes and carriage of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 C c.444C >G minor allele for patients with non-alcoholic fatty liver disease (NAFLD).3,4 HCC incidence is 89% and 78% higher, in males and females respectively, in the most deprived quintile compared with the least.5 Incidence rates in Europe and America have increased since the 1990s, although in recent years these have plateaued most likely as a result of the success of direct-acting antiviral therapy for hepatitis C virus (HCV) infection.6 Modelling from the UK suggests that HCC incidence is expected to increase 40% before 2035 however, and mortality rates are predicted to rise further, in stark contrast to those of other cancers.7

The estimated increase in HCC incidence reflects the emergence of NAFLD as a leading cause of PLC, driven by the obesity and type 2 diabetes (T2D) epidemics.8,9 Estes *et al.* forecast that the incidence of NAFLD HCC will increase by 137% by 2030 in the United States.10 When one reflects on the widespread use and effectiveness of direct-acting antiviral therapy for HCV and the rise in vaccination against hepatitis B virus (HBV) infection, it is clear that NAFLD will become the dominant aetiological driver of HCC.

Despite the potential for curative treatment, many patients with HCC are not eligible for this, either due to advanced tumour stage, poor liver function or low performance status.11 Early diagnosis of HCC is vital as the 1-yr survival is 78% (TNM stage 1) *vs.* 20% for those diagnosed at the latest stage (TNM stage 4).12 The importance of detection of small tumours translates into an increased likelihood of effective treatment and improvement in overall survival.13 Better early detection of liver disease and HCC is a priority for health services.6,14 Given that cirrhosis is the leading cause of HCC, international guidelines advise that all people with NAFLD-related cirrhosis are surveyed for HCC every 6 months via transabdominal ultrasonography (USS).15–17 While contrast-enhanced liver computed tomography (CT) and magnetic resonance imaging (MRI) have been shown to be more sensitive for HCC detection,18 the cost, availability and impact on diagnostic services would prohibit their use as a surveillance tool using the current model of six monthly screening in all at risk patients.19,20 Their use also requires the need for contrast agents, and radiation exposure in the case of CT. In this narrative review we explore the challenges for HCC surveillance in patients with NAFLD, the performance of USS for people with NAFLD compared to other subpopulations and the latest evidence regarding surveillance timing, the use of alpha fetoprotein (AFP), contrast-enhanced USS and cost-effectiveness data. We discuss emerging surveillance tools and provide a summary of best clinical practice.

**Non-alcoholic fatty liver disease**

NAFLD is the leading cause of chronic liver disease in Europe with an overall prevalence significantly higher in men than in women (39.7% vs 25.6%, p<0.0001).21 NAFLD encompasses a spectrum of clinical entities progressing from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), hepatic fibrosis and cirrhosis. Movement between these stages is dynamic prior to the development of cirrhosis. Prevalence rates of NAFLD are estimated to be 10-30% in the general population, 50-90% in people with obesity and 56% in people with T2D.22,23 NAFLD is a metabolic disease with insulin resistance as a central pathophysiological defect,24 and as such a recent consensus group has proposed a change in nomenclature to metabolic-dysfunction associated fatty liver disease (MAFLD) characterised by liver steatosis (radiologically evident) and concomitant metabolic risk factors.25 While excess fat accumulation in the liver itself in many cases may be of no long-term significance to liver health, hepatic steatosis can progress to liver fibrosis in up to 40%.26,27 It is the presence of advancing liver fibrosis and cirrhosis that is associated with an increased risk of liver-related mortality including HCC,26,28,29 and incident cardiovascular disease.30 While traditionally liver fibrosis was staged at liver biopsy, there has been a huge expansion over the last two decades in the use of non-invasive fibrosis tests.31 These include simple algorithms (eg fibrosis-4 (FIB-4) score, NAFLD fibrosis score), serum biomarkers (eg the enhanced liver fibrosis (ELF) test), and shear wave elastography (transient elastography, TE [Fibroscan®],32 liver ultrasound elastography,33 and magnetic resonance elastography).34 Sequential use of more than one test has been shown to reduce the need for liver biopsy.32 In addition to the oncogenic risk posed by NAFLD, obesity and diabetes, observational studies suggest an elevated risk of HCC associated with the use of insulin and sulphonylureas.4,35 There is also emerging evidence of an association between air pollution, incidence of NAFLD36 and HCC mortality.37Interestingly the molecular signature associated with NAFLD-HCC has recently been found to differ to that associated with non-NAFLD HCC, including higher rates of the ACVR2A mutations (a potential tumour suppressant).38

**Challenges presented by the emergence of non-alcoholic fatty liver disease as a leading cause of hepatocellular carcinoma**

The emergence of NAFLD as a leading cause of HCC presents new and unique challenges for hepatologists, metabolic, obesity and diabetes physicians, oncologists and hepatobiliary surgeons.

1. *Disease burden* Current and predicted prevalence levels of NAFLD means that the overall contribution of NAFLD to the global HCC burden is likely to surpass that of HCV.39 Estimates of global trends in the burden of live cancer using the methodology framework of the Global Burden of Disease study have identified that NASH has the fastest growing age standardised death rate for HCC.40 A large cohort study from the Unites States Scientific Registry of Transplant Recipients has shown that 18% of individuals listed for liver transplant, with an indication of HCC, have NASH (the 2nd most common cause after HCV), and that NAFLD is the fastest growing cause of HCC in liver transplant candidates.41 Case series from the UK (n=632)42 and US (n=4,406)43 have identified that 38% and 59% of cases of HCC may be attributable to NAFLD. While HCC incidence rates are similar between patients with NAFLD cirrhosis and HCV cirrhosis, NAFLD is associated with a comparatively low HCC risk compared to HCV overall **(Table 1)**.44,45 This has implications on the cost-effectiveness of USS based HCC surveillance in this group.

*(ii) Presentation of HCC outside of a surveillance programme* While overall survival appears comparable to other aetiologies of HCC, patients with NAFLD-HCC have been found to have a reduced disease-free survival than patients with non-NAFLD HCC.46 This could be explained by the finding that patients with NAFLD-HCC are more likely to have presented with cancer detected outside of a surveillance programme (67.2% *vs*. 44.3% according to meta-analysis data), and with larger tumours (although overall Barcelona Clinic Liver Cancer (BCLC) stage is comparable).46 Several factors are likely to account for this. Two meta-analyses found that 38-39% of patients with NAFLD-HCC were not cirrhotic at presentation *vs.* 14-15% for other aetiologies of chronic liver disease.46,47 This may occur as a result of genetic and oncogenic factors related to obesity, T2D, liver steatosis and hepatic oxidative stress.48 Furthermore a significant proportion of patients with NAFLD presenting with HCC, including those with cirrhosis, have undiagnosed pre-existing liver disease and thus are not enrolled in HCC surveillance.49

(iii) *Low sensitivity of USS* *for the detection of early HCC* As discussed below, ultrasound sensitivity for the detection of HCC in people with NAFLD is suboptimal, largely as a result of central obesity and the presence of hepatic steatosis. Reliance on this imaging modality for HCC surveillance therefore places patients with NAFLD at a disadvantage.

**Performance of ultrasound for detection of hepatocellular carcinoma in patients with cirrhosis (all aetiologies) and chronic hepatitis B virus infection**

USS has many favourable attributes as a surveillance tool: there are no associated risks, costs are moderate, it has high levels of acceptability and achieves high sensitivities for the detection of HCC in certain patient groups (slim, non-cirrhotic). It is also possible to comment on features of cirrhosis and portal hypertension, and where Doppler is used, USS can detect portal vein thrombosis, all of which will guide appropriate management of patients with HCC. Challenges include the detection of very early HCC, where there is a single cancerous nodule ≤ 2cm (BCLC stage 0), and those that meet the Milan criteria (one nodule < 5cm or three nodules each < 3cm in diameter, without gross vascular invasion). The distinction between HCC and regenerating nodules, found in patients with cirrhosis, is also not possible on standard USS. Finally, the experience of the operator is a further factor that impacts on usefulness of ultrasound in this setting.

The use of USS for HCC surveillance was first recommended based on a landmark randomised trial in China of 18,816 patients with hepatitis B or chronic hepatitis.50 The intervention group received six monthly USS plus AFP and these individuals experienced a 37% reduction in mortality. There have been no randomised trials in Western countries. A meta-analysis of prospective studies published up to 2007 confirmed that USS detected the majority of tumours before they presented clinically (94% sensitivity), however it was less effective for the detection of early HCC (63% sensitivity).51 Biannual surveillance increased the sensitivity to 70% for detecting early stage HCC.51 In these studies, there was a mixed aetiology of liver disease although the majority of patients had chronic HCV infection.51 A systematic review of 14 cross-sectional studies reported that USS had high levels of specificity for HCC detection, but was only 60% sensitive.52 Where studies used explanted liver as the gold standard, sensitivities for USS ranged from 58% to 89% in populations from the United States.53–55 An analysis of 202 patients who received a liver transplant for HCC due to mixed aetiologies, reported that USS had a 46% sensitivity for HCC detection compared to 65% for CT and MRI.18 For lesions less than 2cm, sensitivity values were just 21% (USS), 40% (CT) and 47% (MRI).18 In 2018 Tzartzeva *et al.* published an updated meta-analysis of 32 studies (1990-2016; 13,367 patients) and identified that USS detected any stage of HCC with an 84% sensitivity (95% confidence interval, CI 76-92%), and early stage HCC with a sensitivity of just 47% (95% CI 33-61%).56 The aetiology of liver disease in this group was mixed, and it is unclear what proportion of people had NAFLD or were overweight.

In the absence of randomised control trials, a large number of observational studies have attempted to determine if biannual USS surveillance for HCC leads to a survival benefit. In 2022 Singal *et al.*  performed a meta-analysis analysing the harms and benefits of ultrasound surveillance in people with cirrhosis (59 studies, 2014-2020; 145,396 participants).57 HCC surveillance was found to be associated with improved early-stage detection (odds ratio, OR 1.86, 95% CI 1.73-1.98), receipt of curative treatment (OR 1.83, 95% CI 1.69-1.97) and overall survival (hazard ratio, HR 0.67, 95% CI 0.61-0.72).57 Only two studies examined whether HCC surveillance was associated with improved outcome in people with NAFLD however.57 Four studies reported on harms associated with surveillance. These occurred in 8.8-27.5% of patients and were mostly mild in severity.57

**Performance of ultrasound for the detection of hepatocellular carcinoma in the context of non-alcoholic fatty liver disease and obesity**

The study populations from the earliest trials looking at the effectiveness of USS surveillance for HCC,50,58 are not truly representative of today’s HCC surveillance population particularly in the West. Specifically, they were based in Asian in populations where chronic hepatis B and C virus were the predominant drivers of cancer. Patients in these studies had low rates of central obesity and liver steatosis, both of which are known to impair ultrasound image quality.59 In addition, not all patients in these cohorts had cirrhosis,50 which can result in difficulties differentiating between an early HCC and regenerating nodules. In terms of cost effectiveness, the annual incidence of HCC in populations with high rates of chronic viral hepatitis is over 5%; this is greater than that for NAFLD cirrhosis (approximately is 0.7-4.0%).60–62 As a result of the factors mentioned above, over 50% of tumours detected in these cohorts were small, leading to a greater than 50% five year survival for patients who were underwent surgery.63 Survival rates may also have been positively influenced by the fact that patients with non-NAFLD causes of HCC are generally younger with fewer comorbidities than patients with NAFLD-HCC.46

The obesity epidemic began in the 1970s and has continued to rise exponentially; 42.4% of Americans currently have a body mass index (BMI) >30 kg/m2.64 The natural history of NAFLD, with potential progression towards cirrhosis and HCC,65 has meant that it is only in the last two decades that end-stage complications of chronic liver disease including HCC have been widely observed in this group. The rise of obesity and NAFLD also has significant implications for HCC surveillance. Reliance on USS for HCC surveillance presents challenges in the NAFLD population, 51% of whom are living with obesity.66 The depth of the subcutaneous fat, with the inherent acoustic-attenuation, leads to poor image definition, impairing earlier HCC detection. An example of how central obesity can obscure visualisation at ultrasound is shown in **Figure 1** in comparison to images from a patient who is lean (**Figure 2**). Recent cohort studies from Europe and America report that USS is inadequate (defined as detection of HCC outside of the Milan criteria) in 20.3-32.2% of people.59,67 In a retrospective cohort study of 941 patients, a higher BMI, NASH-related cirrhosis, Child Pugh B or C cirrhosis and alcohol-related cirrhosis were all independently associated with inadequate USS quality in multivariable analysis.59 Inadequate quality was observed in 9.3%, 18.0%, 22.8%, 35.5% and 39.3% of people of normal weight, or with overweight, obesity class I, obesity class II, and morbid obesity respectively.59 USS exams were inadequate in 34.6% of patients with NASH-related cirrhosis, in comparison to 15.0% of patients with other aetiologies of cirrhosis.59 These factors lead to under-recognition of small or early stage HCC nodules. These finding were confirmed by Esfeh *et al.* who report that USS has a sensitivity for HCC detection of 59% in people without obesity and 19% for people with obesity in a populations of 116 liver transplant recipients.68 In a similar study of 352 consecutive patients undergoing liver transplant assessment for HCC, univariate analysis identified that obesity (sensitivity 76% for BMI ≥ 30 kg/m2 *vs*. 87% for BMI < 30 kg/m2, p=0.01), and an aetiology of NAFLD (sensitivity 59% *vs.* 84%; p=0.02).69 In 2021 Kim *et al.* performed a meta-analysis to evaluate the incidence of USS surveillance failures in detection of early stage HCC, and to determine risk factors for this.70 A total of 18 studies (21,467 individuals undergoing surveillance) were included. The pooled incidence of surveillance failure (defined as the number of surveillance failure patients / number of patients who underwent surveillance) was 2.2% (95% CI 0.9%-5.4%) for USS alone and 2.6% (95% CI 1.8%-3.9%) for USS plus AFP. A BMI of 30 or more was significantly associated with surveillance failure (OR 1.38, 95% CI 1.02-1.86). Overall, 31.2% of detected HCC was diagnosed beyond the early stage.70 The authors therefore concluded that the use of USS for HCC surveillance appears limited.

As part of their recent meta-analysis described above Singal et al performed a subgroup analysis of studies stratified according to the proportion of patients with NAFLD.57 The researchers report similar point estimates for the association between surveillance and early detection of HCC (relative risk, RR 1.86, 2.23, and 2.04, respectively) and receipt of curative treatment (RR 1.79, 2.06, and 2.02, respectively) for studies with < 10%, 10-20% and > 20% of patients with NAFLD.57 Only two studies out of 59 specifically examined the benefits of HCC surveillance in the NAFLD cohort. Aby et al (retrospective study, n=99 NASH cirrhosis) reported no association with receipt of curative treatment (45.4% vs. 51.7%, p=0.72),71 whereas Lo et al (retrospective study, n=93 NAFLD cirrhosis) found a significant association with early-stage detection 68.2% vs. 29.7%, *p*=0.001 with surveillance, however this did not translate into improved survival.72

**Screening schedule for ultrasound surveillance**

The literature suggests that it takes approximately 4-12 months for an undetectable lesion to reach 2 cm in size.73,74 This has helped inform a six monthly surveillance interval for people with cirrhosis with the aim of detecting tumours less than 3 cm in diameter. A 12 monthly interval has been shown to result in reduced detection rates for early cancer and reduced survival.75 A multi-centre randomised trial reported no benefit for earlier detection of cancer with a three monthly *vs.* six monthly regime in people with cirrhosis, although this was found to be limited by the recall procedure.76 Unfortunately patients with NAFLD cirrhosis did not meet the inclusion criteria for this trial.

**Cost effectiveness of ultrasound surveillance for hepatocellular carcinoma detection**

Markov modelling suggests that six monthly USS surveillance for HCC in people with cirrhosis increases quality-adjusted life expectancy by 8.6 months overall and 3.5 years in patients with small treated tumors.20 Biannual USS surveillance had an incremental cost-effectiveness ratio of $30,700 per quality-adjusted life year (QALY) gained, and was more cost effective than annual USS, biannual USS with AFP, annual/biannual CT, and annual MRI, using a threshold of $50,000 per QALY gained.20 Where USS sensitivity dropped below 65%, or the specificity of AFP exceeded 95%, combined USS and AFP surveillance was preferred.20 The incremental cost-effectiveness ratio of biannual CT and annual MRI consistently exceed $100,000/QALY.20

**Addition of alpha-fetoprotein to ultrasound surveillance**

Elevated serum AFP concentration, particularly sustained high levels, can indicate a possible HCC, however there is only weak evidence to support its use in HCC surveillance. In a study of 88 patients, the inclusion of AFP in the surveillance protocol led to detection of an additional 6-8% of HCC cases *vs.* those detected by USS alone.77 Poor performance relates to the fact that up to 24% of early HCCs present with normal AFP levels (particularly patients without cirrhosis/normal transaminase levels, as frequently occurs with NAFLD-HCC).78 Indeed a greater proportion of people with NAFLD-related HCC are AFP non-secretors compared to people with other drivers of liver cancer.79,80 Furthermore, AFP levels fluctuate with active liver inflammation leading to false positive results with viral and alcoholic hepatitis. In a meta-analysis by Singal *et al.* (2009, 1,116 patients), the pooled sensitivity of USS for the detection of early HCC increased from 63% to 69% with the addition of AFP (although this did not reach statistical significance).51 A more recent meta-analysis (Tzartzeva *et al*, 2018, 13,367 patients) reported that AFP measurement improved sensitivity rates from 45% to 63% for early HCC, however USS alone detected HCC with a higher specificity than USS plus AFP.56 Few studies have looked at the use of AFP for surveillance, rather than as a diagnostic test. The only randomised trial of this type used AFP to see if this could lead to early cancer detection in a population of Chinese men who were hepatitis B surface antigen positive.81 The study found that screening with AFP led to earlier diagnosis of HCC, but did not result in an overall reduction in mortality. There is an important evidence gap to examine the effectiveness and cost-effectiveness of AFP in addition to USS for surveillance in Western populations, including patients with cirrhosis and NAFLD.

The American Association for the Study of Liver Disease (AASLD) guidelines stateit is not possible to determine whether USS alone or the combination of USS plus AFP, leads to a greater improvement in survival.16 Similarly, the European Association for the Study of the Liver (EASL) conclude that“insufficient data are available regarding the diagnostic accuracy of AFP in patients with adequate treatment of the aetiological cause of liver disease making any calculation of the cost-effectiveness impossible to date”.15 In contrast, the Asia–Pacific practice guidelines do recommend the use of AFP in addition to USS for surveillance, with the caveat that AFP is not recommended as a confirmatory test in small HCCs and the AFP cut-off value should be 200 ng/mL, although a lower value can be used in a population with hepatitis virus suppression or eradication.17 While no specific recommendations have been made regarding people with NAFLD, the clinical utility of AFP in this setting is thought to be low.15,16 AFP does however play an important prognostic role in patients with established HCC.82,83

**Contrast-enhanced ultrasound for hepatocellular carcinoma surveillance**

There has been interest in using intravenous contrast agents (stabilised microbubbles containing air or other gases) to enhance the performance of USS for the detection of early HCC. These contrast agents are safe and are not renally cleared (unlike iodinated agents used for CT or MRI). Contrast-enhanced USS (CEUS) allows real-time dynamic imaging (performed continuously for the first minute), permitting the detection of arterial neoangiogenesis. This is followed by intermittent scanning every 30-60 seconds for a further five minutes to examine washout. The degree and time of onset of the washout can help discriminate HCC (mild, late washout) from intrahepatic cholangiocarcinoma and other non-HCC tumours (marked, early washout).84 CEUS also benefits from the fact that arterioportal shunts seen at CT and MRI are not visible, and in the setting of cirrhosis, any lesion demonstrating arterial enhancement is likely to be malignant or pre-malignant.84 CEUS does not enhance the ability of USS to detect small tumour foci however.85 This may be related to the fact that comprehensive assessment of the whole liver cannot be performed during the short arterial phase. Also, not all well-differentiated HCCs show arterial enhancement.86 CEUS is more expensive that non-contrast ultrasound, requiring expertise and specialised equipment. For the characterisation of known focal liver lesions, costs are comparable to CT, but CEUS is more cost-effective than MRI.87 Therefore CEUS is not recommended for surveillance, but is recommended for diagnostic purposes in patients at high risk of HCC.15,16,84

**Emerging tools for HCC surveillance**

There has been some interest in adapting existing CT and MRI protocols to improve their acceptability as surveillance tools. In a prospective single armed study, biannual two-phase low-dose CT has been trialled for HCC surveillance, which showed significantly higher levels of sensitivity (83.3% *vs.* 29.2%) than USS.88 Abbreviated MRI examination involves using a shortened MRI protocol with fewer sequences, specifically designed to detect early-stage HCC.89 Three strategies have been trialled: (i) non-contrast MRI, (ii) diffusion-weighted imaging, dynamic contrast-enhanced and (iii) hepatobiliary phase contrast-enhanced abbreviated MRI. These techniques were evaluated in a meta-analysis which included three prospective and 12 retrospective studies: 2,807 patients, 917 with HCC. Abbreviated MRI achieved high levels of sensitivity (69% for tumours < 2 cm, 86% for tumours ≥2 cm; 82% overall *vs.* 53% for USS).90 Non-contrast and contrast abbreviated MRI were comparable in terms of sensitivity (86% *vs*. 87%) and specificity values (94% *vs.* 94%).88 Non-contrast MRI is comparable to USS in terms of cost, and has the benefit of not requiring exposure to contrast or radiation, it may therefore prove to be an effective surveillance tool in patients with suboptimal USS imaging. We await the results of key trials comparing non-contrast MRI with USS for HCC surveillance (NCT02551250, MAGNUS-HCC; NCT04455932; NCT02514434, MIRACLE-HCC) to inform whether non-contrast MRI offers a benefit in terms of increased sensitivity for detection of early lesions and survival. These studies will also suggest an optimal surveillance schedule for this technique.

Substantial investment is being directed towards exploring the use of biomarkers for detecting early disease. Published examples, include the GALAD score (comprising age, gender, AFP, the lens culinaris-agglutinin-reactive fraction of AFP, and Des-Gamma-Carboxy Prothrombin (DCP) (also known as prothrombin induced by vitamin K absence II (PIVKA II)), which has been shown to detect any stage HCC in patients with NASH with an area under the curve (AUC) of 0.96, and HCC within the Milan criteria with an AUC of 0.91 (sensitivity of 68% and specificity of 95%).91 It requires specialist tests however and has not yet been prospectively validated, although trials are underway (NCT05342350). DCP has been shown to have a sensitivity and specificity of 71% and 84% respectively for the detection of HCC,92 however DCP levels are associated with more advanced tumour stage and portal vein invasion, a limitation for early detection.93 Recent observational studies from Japan have identified that IgM-free apoptosis inhibitor of macrophage (AIM) serum levels are a sensitive diagnostic marker for NASH-HCC, and that AIM activation appears before HCC is diagnostically detectable.94,95 Larger validation studies are required however. Another approach is liquid biopsy (the analysis of tumour components in particular circulating tumour DNA [ctDNA], circulating tumour cells or extracellular vesicles). Oncoguard Liver (a composite of three ctDNA methylation genes, AFP and gender) has demonstrated high levels of sensitivity and specificity.96 The HelioLiver Test (a multi‐analyte blood test combining ctDNA methylation panel, clinical variables, and protein tumour markers) has demonstrated an AUC of over 0.95 in a phase II study,97 and is currently undergoing prospective validation. Liquid biopsy is prone to detection errors however as ctDNA generally comprises < 2% of circulating DNA, and less in early HCC.

In terms of risk stratification, the aMAP score was developed using data from prospective studies and randomized control trials and was found to be predictive of HCC at five years in patients with different aetiologies of liver disease, however only 5% had NAFLD.98 The ‘HCC risk score’ developed using the Veterans Affairs healthcare dataset, identifies patients with NAFLD cirrhosis at risk of HCC, but is not validated in people without cirrhosis.99 Given the association noted between PNPLA3 and HCC,100 there has been interest in whether this may serve as a useful tool for risk stratification. This association has been found to be less significant in patients with NAFLD however,101 and recent analysis of the performance of a polygenic risk score incorporating PNPLA3 reported only moderate accuracy in predicting which patients with NAFLD are at greatest risk of HCC.102 The prognostic liver signature (PLS)–NAFLD, a 133 gene signature, has been shown to be predictive of HCC risk but is currently limited by availability and cost.103

Ultimately better tools are needed to risk stratify individuals at risk of HCC and to tailor testing, and perhaps the time interval for surveillance accordingly to support a move towards precision screening for HCC.104 Given the experience and time spent on HCC surveillance in many countries, improved patient selection and testing is urgently required. Consortia, including NIMBLE (Non-Invasive Biomarkers of Metabolic Liver Disease), LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) and DeLIVER (Early detection of hepatocellular liver cancer), are pursuing the discovery of novel biomarkers for use in this clinical context, and may be used with USS, or when USS performance is suboptimal.

Shear wave elastography, a non-invasive marker for the prediction of liver fibrosis which uses a normal B-mode ultrasound probe has been shown to be predictive of HCC risk in hepatitis B and C virus infection.105,106 In addition it may be clinically useful in differentiating between benign and malignant lesions.107 Further validation is required however.

Finally, while newer USS devices have the additional capacity to measure grades of liver steatosis,108 it is unclear how this would benefit the HCC surveillance population where the majority of patients will have cirrhosis.

**Best clinical practice**

International guidelines acknowledge the limited performance of USS in patients with central obesity and marked parenchymal heterogeneity. Yet USS remains the primary recommended imaging technique for HCC surveillance (**Table 2**), considering its high sensitivity in the absence of these factors, safety and proven cost effectiveness. The AASLD guidelines advise clinicians to utilise CT or MRI, with or without AFP, in patients every six months where USS is documented to be inadequate.16 The latest American Gastroenterology Association (AGA) clinical practice update on screening and surveillance for HCC in patients with NAFLD, support this approach, and emphasise that the adequacy of USS should be consistently reported including descriptions of parenchyma heterogeneity, visualization of the entire liver, and beam attenuation, as these factors may be impaired in the presence of obesity.109 These recommendations reflect the USS LI-RADS (Liver Reporting and Data System) visualisation scores (A - No or minimal limitation, B - Moderate limitation, the examination may obscure small masses, C - Severe limitation, the examination may miss focal liver lesions).110 CT or MRI surveillance is advised where USS quality is graded as C, or in some cases B.109 This grading system has not been validated however and there is some uncertainty around the approach to patients in category B. The cost-effectiveness of this strategy has not been investigated and this could have significant implications for health care providers and systems, as the number of patients qualifying for cross sectional imaging is likely to continue to grow over the coming years.99

We propose a pragmatic approach based on practice in our centre as described in **Figure 3**. We encourage documentation of the USS quality as either ‘satisfactory’ or ‘suboptimal’ for the detection of focal lesions (Box 1). With suboptimal imaging, we suggest patients fit for curative treatment, instead receive an abbreviated MRI scan (we await the results of ongoing trails to determine if a 6 or 12 monthly surveillance schedule is preferable). Where MRI is contraindicated, we suggest physicians consult with their radiology department regarding the use of CT and optimal timing of this on a case-by-case basis. Acknowledging the effectiveness and cost-effectiveness of this approach has not been tested within a randomised control trial, the authors feel this approach should be a priority for future research

**Box 1. Binary assessment of USS adequacy**

**Satisfactory:** No or minimal limitation (liver homogenous, or minimally heterogenous, minimal beam attenuation or shadowing, and/or liver visualisation in near entirety)

**Suboptimal:** Moderate limitation, the examination may obscure small masses (liver moderately heterogenous, moderate beam attenuation or shadowing, and/or some portions of liver or diaphragm not visualised), or severe limitation (liver severely heterogenous, severe beam attenuation or shadowing, and/or > 50% of liver or > 50% of diaphragm not visualised)

**Should patients with non-alcoholic fatty liver disease who do not have cirrhosis undergo hepatocellular carcinoma surveillance?**

There is currently insufficient evidence to recommend HCC surveillance in patients with NAFLD *without cirrhosis*.111 On one hand the overall risk of HCC is extremely low (15% HCC incidence at 10 years for people with NAFLD cirrhosis, *vs.* 2.7% for those without cirrhosis),112 on the other hand up to 40% of people with NAFLD develop HCC in the absence of cirrhosis.46 People with NAFLD *without cirrhosis* have better liver function, are younger, have fewer comorbidities and better performance status than those with NAFLD *with cirrhosis*, increasing their likelihood of receiving curative treatment, if their tumour was diagnosed at an early stage. They would also have a lower probability of death from decompensated liver disease, extrahepatic cancer and cardiovascular disease during surveillance. It is impractical to survey all patients with NAFLD for HCC, thus more comprehensive risk stratification within this group would be beneficial. Liver fibrosis is a key risk factor for HCC in people with NAFLD. In a prospective study, the HCC incidence rate per 1000 person-years was found to be 0.34 for advanced fibrosis *vs*. 0.04 for nil or minimally significant fibrosis defined histologically.113 A similar association has been found where non-invasive serum fibrosis tests are used. Analysis of data from the Veterans Health Administration identified that a FIB-4 score > 2.67 is predictive of high incidence rates of HCC (0.39 per 1000 person years *vs*. 0.04 per 1000 person years in those with a persistently low FIB-4).114 There is also evidence of a positive relationship between liver stiffness measurement obtained at fibroscan and disease activity115 including HCC incidence.116

Guidelines disagree about the merits of HCC surveillance in patients with non-cirrhotic NAFLD (**Table 2**). EASL, in contrast to the American (AASLD) and Asia-Pacific guidelines, recommend people with the metabolic syndrome or NASH affected by severe fibrosis should undergo surveillance.15–17 EASL state that all “non-cirrhotic fibrosis stage 3 patients, regardless of aetiology may be considered for surveillance based on an individual risk assessment”.15 The recent AGA update on HCC surveillance in NAFLD recommends HCC screening in those with evidence of “advanced liver fibrosis or cirrhosis” determined by combining at least two non-invasive tests: point-of-care tests (e.g. FIB-4 score), specialised blood tests (e.g. ELF test ), imaging-based tests (e.g. TE).109 The cut-offs selected (16.1kPa for TE) are within the cirrhotic range however.117 This approach is largely driven by clinical consensus opinion as there is minimal evidence to support these cut-offs, or the use of non-invasive tests in this setting currently. 104

**Conclusion**

Mortality rates from HCC are increasing, driven largely by the continued rise in the prevalence of NAFLD in many countries. Outcomes for people with HCC are strongly associated with early detection, thus optimisation of HCC surveillance techniques including USS is a major priority for research in this field. Patients with NAFLD are under-represented in HCC surveillance compared to other aetiologies of liver disease due to high rates of undetected disease in the community, and a higher prevalence of patients presenting with HCC in the absence of cirrhosis. Better tools are needed to help identify patients with NAFLD at risk of HCC. USS may be suboptimal for early disease detection for patients with obesity and NAFLD. Guidance from the AGA on recording the image quality of USS should be instituted and additional imaging, with abbreviated MRI (or CT where MRI is contraindicated) should be decided on a case-by-case basis. Novel approaches including the GALAD and aMAP score, in addition to other biomarkers, still require further evaluation prior to becoming part of routine surveillance

**DECLARATIONS**

**Acknowledgments**

None

**Authors’ contributions**

TH wrote the manuscript draft. All other authors contributed significantly towards the reviewing and editing the manuscript.

**Availability of data and materials**

Not applicable.

**Financial support and sponsorship**

None.

**Conflicts of interest**

All authors declared that there are no conflicts of interest.

**Ethical approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Copyright**

© The Author(s) 2018.

**References**

1. Kocarnik JM, Compton K, Dean FE, et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. *JAMA Oncol*. 2022;8(3):420-444. doi:10.1001/JAMAONCOL.2021.6987

2. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. *Nature Reviews Disease Primers 2021 7:1*. 2021;7(1):1-28. doi:10.1038/s41572-020-00240-3

3. Burton A, Balachandrakumar VK, Driver RJ, et al. Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England. *British Journal of Cancer 2021 126:5*. 2021;126(5):804-814. doi:10.1038/s41416-021-01509-4

4. Hydes TJ, Cuthbertson DJ, Graef S, et al. The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival. *Clin Ther*. 2022;44(2):257-268. doi:10.1016/j.clinthera.2021.12.011

5. UK CR. Cancer Research UK. Liver cancer incidence statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/liver-cancer/incidence#ref-2

6. National Cancer Institute. *Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer*.; 2022. doi:https://seer.cancer.gov/statfacts/html/livibd.html

7. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in the UK until 2035. *Br J Cancer*. 2016;115(9):1147-1155. doi:10.1038/bjc.2016.304

8. Burton A, Tataru D, Driver R, et al. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. *Journal of Hepatology reports : innovation in hepatology*. 2021;3(2). doi:10.1016/J.JHEPR.2021.100232

9. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. *Hepatology*. 2015;62(6):1723-1730. doi:10.1002/hep.28123

10. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology*. 2018;67(1):123-133. doi:10.1002/hep.29466

11. European Association for the Study of the Liver. *Management of Alcoholic Liver Disease, EASL Clinical Practice Guidelines*.; 2018. doi:10.1016/j.jhep.2018.03.018

12. Office for National Statistics. *Cancer Survival by Stage at Diagnosis for England*.; 2019. doi:https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancersurvivalratescancersurvivalinenglandadultsdiagnosed

13. De Toni EN, Schlesinger-Raab A, Fuchs M, et al. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: A population-based study. *Gut*. 2020;69(1):168-176. doi:10.1136/GUTJNL-2018-318193

14. Williams R, Aspinall R, Bellis M, et al. Lancet Commission. Addressing the Crisis of the Liver Disease in the UK: A blueprint for attaining excellence in healthcare for liver disease and reducing premature mortality from the major lifestyle issues of excess alcohol consumption, obesity and viral. *The Lancet*. 2014;384(9958):1953-1997. doi:10.1016/S0140-6736(14)61838-9

15. Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol*. 2018;69:182-236. doi:10.1016/j.jhep.2018.03.019

16. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Purpose and Scope. 2018;68(2). doi:10.1002/hep.29913

17. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int*. 2017;11:317-370. doi:10.1007/s12072-017-9799-9

18. Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2011;9(2):161-167. doi:10.1016/J.CGH.2010.09.017

19. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. *Gut*. 2010;59(5):638-644. doi:10.1136/GUT.2009.187286

20. Andersson KL, Salomon JA, Chung RT, Goldie SJ. Cost-Effectiveness of Alternative Surveillance Strategies for Hepatocellular Carcinoma in Patients with Cirrhosis. *Clin Gastroenterol Hepatol*. 2008;6(12):1418. doi:10.1016/J.CGH.2008.08.005

21. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2022;0(0). doi:10.1016/S2468-1253(22)00165-0

22. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther*. 2011;34(3):274-285. doi:10.1111/j.1365-2036.2011.04724.x

23. Stål P. Liver fibrosis in non-alcoholic fatty liver disease-Diagnostic challenge with prognostic significance. *World J Gastroenterol*. 2015;21(39):11077-11087. doi:10.3748/wjg.v21.i39.11077

24. Targher G, Tilg H, Byrne CD. NAFLD: a multisystem disease requiring a multidisciplinary and holistic approach. *Lancet Global Health*. Published online 2021. doi:10.1016/S2468-1253(21)00020-0

25. Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. *J Hepatol*. 2020;73(1):202-209. doi:10.1016/j.jhep.2020.03.039

26. De A, Duseja A. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. *J Clin Exp Hepatol*. 2020;10(3):255-262. doi:10.1016/j.jceh.2019.09.005

27. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. *Clinical Gastroenterology and Hepatology*. 2015;13(4):643-654.e9. doi:10.1016/j.cgh.2014.04.014

28. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Hepatology*. 2017;65(5):1557-1565. doi:10.1002/hep.29085

29. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology*. 2015;61(5):1547-1554. doi:10.1002/hep.27368

30. Baratta F, Pastori D, Angelico F, et al. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. *Clinical Gastroenterology and Hepatology*. 2020;18(10):2324-2331.e4. doi:10.1016/j.cgh.2019.12.026

31. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *J Hepatol*. 2021;75(3):659-689. doi:10.1016/J.JHEP.2021.05.025

32. Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*. 2022;71(5):1006-1019. doi:10.1136/GUTJNL-2021-324243

33. Dietrich CF, Bamber J, Berzigotti A, et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). *Ultraschall Med*. 2017;38(4):e16-e47. doi:10.1055/S-0043-103952

34. Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. *Eur Radiol*. 2016;26(5):1431-1440. doi:10.1007/S00330-015-3949-Z

35. Lee JY, Jang SY, Nam CM, Kang ES. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study. *Sci Rep*. 2019;9(1). doi:10.1038/S41598-019-44447-1

36. Guo B, Guo Y, Nima Q, et al. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. *J Hepatol*. 2022;76(3):518-525. doi:10.1016/J.JHEP.2021.10.016

37. Gan T, Bambrick H, Tong S, Hu W. Air pollution and liver cancer: A systematic review. *Journal of Environmental Sciences*. 2023;126:817-826. doi:10.1016/J.JES.2022.05.037

38. Pinyol R, Torrecilla S, Wang H, et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. *J Hepatol*. 2021;75(4):865-878. doi:10.1016/J.JHEP.2021.04.049

39. Baffy G. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. *Journal Clinical Translational Hepatology*. 2013;1:131-137. doi:10.14218/JCTH.2013.00005

40. Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. *Cell Metab*. 2022;34(7):969-977.e2. doi:10.1016/J.CMET.2022.05.003

41. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. *Clinical Gastroenterology and Hepatology*. 2019;17(4):748-755.e3. doi:10.1016/j.cgh.2018.05.057

42. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. *J Hepatol*. 2014;60(1):110-117. doi:10.1016/j.jhep.2013.08.011

43. Sanyal, A.; Poklepovic, A.; Moyneur, E.; Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. *Curr Med Res Opin*. 2010;26:2183-2191. doi:10.1185/03007995.2010.506375

44. Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. *Clin Gastroenterol Hepatol*. 2022;20(2):283-292.e10. doi:10.1016/J.CGH.2021.05.002

45. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J Hepatol*. 2017;68(1):25-32. doi:10.1016/J.JHEP.2017.08.030

46. Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. *Lancet Oncol*. 2022;23(4):521-530. doi:10.1016/S1470-2045(22)00078-X

47. Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. *Aliment Pharmacol Ther*. 2018;48(7):696-703. doi:10.1111/apt.14937

48. Liu Y, Patman G, Leathart J, et al. Carriage of the PNPLA3 rs738409 C & G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *J Hepatol*. 2014;61(1):75-81. doi:10.1016/j.jhep.2014.02.030

49. Hydes TJ, Matthews C, Kumar V, et al. Lack of NAFLD-related HCC surveillance may explain more advanced stage at diagnosis and worse median survival. *BASL annual meeting*. Published online 2022.

50. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol*. 2004;130(7):417-422. doi:10.1007/S00432-004-0552-0

51. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Aliment Pharmacol Ther*. 2009;30(1):37-47. doi:10.1111/J.1365-2036.2009.04014.X

52. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. *Am J Gastroenterol*. 2006;101(3):513-523. doi:10.1111/J.1572-0241.2006.00467.X

53. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. *Hepatology*. 2001;33(6):1394-1403. doi:10.1053/jhep.2001.24563

54. Teefey SA, Hildeboldt CC, Dehdashti F, et al. Detection of primary hepatic malignancy in liver transplant candidates: Prospective comparison of CT, MR imaging, US, and PET. *Radiology*. 2003;226(2):533-542. doi:10.1148/radiol.2262011980

55. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. *Am J Gastroenterol*. 2000;95(6):1535-1538. doi:10.1111/j.1572-0241.2000.02091.x

56. Tzartzeva K, Obi J, Rich NE, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. *Gastroenterology*. 2018;154(6):1706-1718.e1. doi:10.1053/j.gastro.2018.01.064

57. Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. *J Hepatol*. 2022;77(1):128-139. doi:10.1016/J.JHEP.2022.01.023

58. Chen THH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. *Int J Cancer*. 2002;98(2):257-261. doi:10.1002/IJC.10122

59. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. *Aliment Pharmacol Ther*. 2017;45(1):169-177. doi:10.1111/APT.13841

60. Sanyal A, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. *Hepatology*. 2006;43(4):682-689. doi:10.1002/HEP.21103

61. Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology*. 2010;51(6):1972-1978. doi:10.1002/hep.23527

62. Yatsuji S, Hashimoto E, Tobari M, Taniai M TK, K. S. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J Gastroenterol Hepatol*. 2009;24:248–254. doi:10.1111/j.1440-1746.2008.05640.x

63. Tang Z, Yu Y, Zhou X. An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. *Journal of Experimental Clinical Cancer Research*. 1984;3:359-366.

64. National Centre for Health Statistics. *National Health and Nutrition Examination Survey, 1999–2018*. doi:https://www.cdc.gov/nchs/nhanes/index.htm

65. Adams LA, Lymp JF, St. Sauver J, et al. The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. *Gastroenterology*. 2005;129(1):113-121. doi:10.1053/j.gastro.2005.04.014

66. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64(1):73-84. doi:10.1002/hep.28431

67. Del Poggio P, Olmi S, Ciccarese F, et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2014;12(11):1927-1933.e2. doi:10.1016/J.CGH.2014.02.025

68. Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. *Clin Mol Hepatol*. 2020;26(1):54-59. doi:10.3350/cmh.2019.0039

69. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. *Liver Transplantation*. 2018;24(9):1171-1177. doi:10.1002/LT.25202

70. Kim DH, Hong SB, Choi SH, et al. Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis. *Gut*. 2022;71(1):212-213. doi:10.1136/GUTJNL-2020-323615

71. Aby E, Phan J, Truong E, Grotts J, Saab S. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis. *J Clin Gastroenterol*. 2019;53(2):142-146. doi:10.1097/MCG.0000000000001075

72. Lo S, Gane E, Bartlett A, Or D. Clinical features and survival of nonalcoholic fatty liver disease-related hepatocellular carcinoma. *Hepatology International* . 2016;10:S437.

73. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. *Hepatology*. 1992;16(1):132-137. doi:10.1002/hep.1840160122

74. Ebara M, Ohto M, Shinagawa T, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. *Gastroenterology*. 1986;90(2):289-298. doi:10.1016/0016-5085(86)90923-6

75. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J Hepatol*. 2010;53(2):291-297. doi:10.1016/j.jhep.2010.03.010

76. Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. *Hepatology*. 2011;54(6):1987-1997. doi:10.1002/hep.24545

77. Biselli M, Conti F, Gramenzi A, et al. A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. *Br J Cancer*. 2015;112(1):69-76. doi:10.1038/bjc.2014.536

78. Giannini EG, Sammito G, Farinati F, et al. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. *Cancer*. 2014;120(14):2150-2157. doi:10.1002/cncr.28706

79. Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. *Hepatology*. 2016;63(3):827-838. doi:10.1002/HEP.28368

80. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. *Hepatology*. 2009;49(3):851-859. doi:10.1002/hep.22734

81. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. *J Med Screen*. 2003;10(4):204-209. doi:10.1258/096914103771773320

82. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. *Gastroenterology*. 2012;143(4). doi:10.1053/J.GASTRO.2012.05.052

83. Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. *Ann Oncol*. 2013;24(10):2565-2570. doi:10.1093/ANNONC/MDT247

84. Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. *Radiology*. 2018;289(3):816. doi:10.1148/RADIOL.2018181494

85. Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. *J Hepatol*. 2008;48(5):848-857. doi:10.1016/j.jhep.2008.02.005

86. Nicolau C, Catalá V, Vilana R, et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: Correlation with cellular differentiation. *Eur Radiol*. 2004;14(6):1092-1099. doi:10.1007/s00330-004-2298-0

87. Smajerova M, Petrasova H, Little J, et al. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis. *World J Gastroenterol*. 2016;22(38):8605-8614. doi:10.3748/wjg.v22.i38.8605

88. Yoon JH, Lee JM, Lee DH, et al. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. *Liver Cancer*. 2020;9(5):503-517. doi:10.1159/000506834

89. An J, Peña MA, Cunha GM, et al. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. *Radiographics*. 2020;40(7):1916-1931. doi:10.1148/RG.2020200104

90. Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. *J Hepatol*. 2021;75(1):108-119. doi:10.1016/j.jhep.2021.01.041

91. Best J, Lars B, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. *Clinical Gastroenterology and Hepatology*. 2020;18(3):728-735. doi:10.1016/j.cgh.2019.11.012

92. Zhu R, Yang J, Xu L, et al. Diagnostic Performance of Des- γ -carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis. *Gastroenterol Res Pract*. 2014;2014. doi:10.1155/2014/529314

93. Hagiwara S, Kudo M, Kawasaki T, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. *J Gastroenterol*. 2006;41(12):1214-1219. doi:10.1007/s00535-006-1950-7

94. Koyama N, Yamazaki T, Kanetsuki Y, et al. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma. *J Gastroenterol*. 2018;53(6):770-779. doi:10.1007/s00535-017-1398-y

95. Okanoue T, Yamaguchi K, Shima T, et al. Serum levels of immunoglobulin M-free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis-associated hepatocellular carcinoma. *Hepatol Res*. 2022;52(12):998-1008. doi:10.1111/HEPR.13826

96. Chalasani NP, Porter K, Bhattacharya A, et al. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*. 2022;20(1):173-182.e7. doi:10.1016/J.CGH.2021.08.010

97. Lin N, Lin Y, Xu J, et al. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. *Hepatol Commun*. 2022;6(7):1753-1763. doi:10.1002/HEP4.1918

98. Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. *J Hepatol*. 2020;73(6):1368-1378. doi:10.1016/j.jhep.2020.07.025

99. Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. *J Hepatol*. 2019;71(3):523-533.

100. Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. *Am J Gastroenterol*. 2014;109(3):325-334. doi:10.1038/AJG.2013.476

101. Yang J, Trépo E, Nahon P, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. *Int J Cancer*. 2019;144(3):533-544. doi:10.1002/IJC.31910

102. Bianco C, Jamialahmadi O, Pelusi S, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. *J Hepatol*. 2021;74(4):775-782. doi:10.1016/J.JHEP.2020.11.024

103. Fujiwara N, Kubota N, Crouchet E, et al. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. *Sci Transl Med*. 2022;14(650). doi:10.1126/SCITRANSLMED.ABO4474/SUPPL\_FILE/SCITRANSLMED.ABO4474\_MDAR\_REPRODUCIBILITY\_CHECKLIST.PDF

104. Singal AG, Sanduzzi-Zamparelli M, Nahon P, et al. International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance. *J Hepatol*. 2023;0(0). doi:10.1016/J.JHEP.2023.02.022

105. Hamada K, Saitoh S, Nishino N, et al. Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response. *PLoS One*. 2018;13(4). doi:10.1371/JOURNAL.PONE.0195173

106. Zhang T, Zhang G, Deng X, et al. APS (age, platelets, 2D shear-wave elastography) score predicts hepatocellular carcinoma in chronic hepatitis B. *Radiology*. 2021;301(2):350-359. doi:10.1148/radiol.2021204700

107. Nacheva-Georgieva EL, Doykov DI, Andonov VN, Doykova KA, Tsvetkova SB. Point Shear Wave Elastography and 2-Dimensional Shear Wave Elastography as a Non-Invasive Method in Differentiating Benign from Malignant Liver Lesions. *Gastroenterology Insights 2022, Vol 13, Pages 296-304*. 2022;13(3):296-304. doi:10.3390/GASTROENT13030030

108. Cassinotto C, Jacq T, Anselme S, et al. Diagnostic Performance of Attenuation to Stage Liver Steatosis with MRI Proton Density Fat Fraction as Reference: A Prospective Comparison of Three US Machines. *Radiology*. 2022;305(2):353-361. doi:10.1148/radiol.212846

109. Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. *Gastroenterology*. 2020;158(6):1822-1830. doi:10.1053/J.GASTRO.2019.12.053

110. LI-RADS ® v2017 US Core. doi:https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-US-Algorithm-Portrait-2017.pdf

111. Torres MCP, Bodini G, Furnari M, et al. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? *Cancers (Basel)*. 2020;12(6):1422. doi:10.3390/cancers12061422

112. Reig M, Gambato M, Man N, et al. Should Patients With NAFLD/NASH Be Surveyed for HCC? *Transplantation*. 2019;103(1):39-44. doi:10.1097/TP.0000000000002361

113. Sanyal AJ, Natta ML Van, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. *https://doi.org/101056/NEJMoa2029349*. 2021;385(17):1559-1569. doi:10.1056/NEJMOA2029349

114. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. *Gastroenterology*. 2018;155(6):1828-1837.e2. doi:10.1053/j.gastro.2018.08.024

115. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol*. 2020;5(4):362-373. doi:10.1016/S2468-1253(19)30383-8

116. Shearer JE, Jones R, Parker R, Ferguson J, Rowe IA. The natural history of advanced chronic liver disease defined by transient elastography. *Clinical Gastroenterology and Hepatology*. Published online March 23, 2022. doi:10.1016/J.CGH.2022.03.015

117. Wong VWS, Vergniol J, Wong GLH, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology*. 2010;51(2):454-462. doi:10.1002/hep.23312